Genisphere’s 3DNA® Dendrimers are made from systematically assembled DNA strands. The firm is exploiting the technology to improve sensitivity in immunoassay and nucleic acid detection platforms, as well as to deliver therapeutics in a highly specific manner.
Clinical-stage biopharma Multicell’s lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). MCT-125 has demonstrated efficacy in a 138 patient Phase IIa clinical trial for the treatment of PMSF.
MCT-485 is cytotoxic agent, and the first in a family of cancer therapeutic candidates based on MultiCell’s TLR3 signalling technology. The candidate acts by directly inducing tumour cell death, and triggering production of TNF-alpha by cancer cells, amplifying both apoptotic effects and triggering a localized immune reaction that has the potential to generalize and curb progression of metastatic cancer, the firm claims.
MCT-485, along with MCT-465 and MCT-475 and are based on MultiCell’s therapeutic antibody and synthetic dsRNA technologies. The immune enhancer MCT-465 is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of cancers including breast carcinoma. MCT-485 is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.
No comments:
Post a Comment